Association of ABO Blood Types and Clinicopathological Features of Prostate Cancer
Table 2
Pathological features of the study population stratified by ABO blood type.
Variables
ABO blood types
non-O ()
valuea
valueb
O ()
A ()
B ()
AB ()
PSA
PSA ≤ 100 (ng/ml)
30.4 ± 27.5
28.0 ± 25.4
31.0 ± 24.5
34.8 ± 31.8
30.4 ± 25.9
0.861
0.999
PSA > 100 (𝑛 (%))
21 (30.9)
27 (40.9)
31 (40.3)
8 (34.8)
66 (39.8)
0.598
0.234
Gleason score
8.03 ± 1.4
8.29 ± 1.2
8.15 ± 1.3
8.00 ± 1.2
8.18 ± 1.2
0.099
0.434
Stage
0.350
0.232
T1
3 (4.3)
1 (1.5)
7 (8.9)
1 (4.3)
9 (5.4)
T2a
17 (24.6)
6 (9.1)
5 (6.3)
3 (13.0)
14 (8.3)
T2b
14 (20.3)
15 (22.7)
17 (21.5)
4 (17.4)
36 (21.4)
T2c
8 (11.6)
9 (13.6)
12 (15.2)
5 (21.7)
26 (15.5)
T3
16 (23.2)
27 (40.9)
28 (35.4)
6 (26.1)
61 (36.3)
T4
11 (15.9)
8 (12.1)
10 (12.7)
4 (17.4)
22 (13.1)
N
0.550
0.542
N0
49 (71)
41 (62.1)
56 (70.9)
14 (60.9)
111 (66.1)
N1
20 (29)
25 (37.9)
23 (29.1)
9 (39.1)
57 (33.9)
M
0.720
0.558
M0
45 (65.2)
38 (57.6)
51 (64.6)
13 (56.5)
102 (60.7)
M1
24 (34.8)
28 (42.4)
28 (35.4)
10 (43.5)
66 (39.3)
High risk
50 (72.5)
57 (86.4)
66 (83.5)
21 (91.3)
144 (85.7)
0.086
0.025
Data are expressed as n (%) or mean ± SD. The bold value indicated statistical significance. PC = prostate cancer; BMI = body mass index; PSA = prostate-specific antigen. valuea for comparison among ABO blood types; valueb for comparison between non-O and O blood types.
